Preparation of hydroxyapatites lebelled with 223Ra and 99mTc and their in vitro stabililty
Authors:
Petra Mičolová; Martin Vlk; Eva Málková; Anna Bajzíková; Ján Kozempel
Authors‘ workplace:
Fakulta jaderná a fyzikálně inženýrská, Katedra jaderné chemie, ČVUT v Praze, ČR
Published in:
NuklMed 2016;5:4-9
Category:
Original Article
Overview
Introduction:
Increasing attention in targeted radionuclide cancer therapy is given to alpha emitters. 223Ra and 99mTc labelled hydroxyapatites (nHAp) are suitable candidates for using in therapy and diagnostics of bone metastases. Moreover, both radionuclides and hydroxyapatites are already approved by Food and Drug Administration Agency (FDA) to be used in a number of applications.
Material and methods:
Nano-hydroxyapatite particles were prepared by precipitation of 1,2 M Ca(NO3)2 . 2H2O with 0,8 M (NH4)2HPO4 at pH 10-–11 and laboratory temperature. Stock 223Ra was prepared from 227Ac/227Th/223Ra generator in our laboratory, which was eluted by 0,7 M HNO3 and methanol (2 : 8). Stock 99mTc was obtained from commercial 99Mo/99mTc generator (DRYTEC™, GE Healthcare) and was eluted with 0.9% saline. Radionuclidic purity was evaluated by gamma-spectrometry with high resolution (in case of 223Ra also by alpha-spectrometry). Two strategies were chosen for nanoparticles labelling i.e. surface sorption of radionuclides and intrinsic incorporation of radionuclides and subsequently stability control in saline was performed during 5 half-lives.
Results:
Surface-labelled nHAp were obtained with yields ranging from 80 to 95 %. In the latter strategy, intrinsically labelled nHAp were obtained in the yields of 90–97 %.
Conclusion:
Labelling yields of intrinsically labelled [223Ra]nHAp were slightly higher than surface-labelled nHAp. The obtained labelling yields of [99mTc]nHAp were comparable in both methods. Released activity was below 8 % in all cases.
Keywords:
99mTc, 223Ra, nanomaterials, hydroxyapatite, therapy and diagnostics, bone metastases
Sources
1. Food and Drug Administration [online]. [cit. 2015-03-16]. Dostupné na: http://www.fda.gov/RegulatoryInformation/Guidances/ucm080224.htm
2. Hossain S, Yamamoto H, Chowdhury EH et al. Fabrication and Intracellular Delivery of Doxorubicin/Carbonate Apatite Nanocomposites: Effect on Growth Retardation of Established Colon Tumor. PLOS ONE 2013;8:doi:10.1371/journal.pone.0060428
3. Iafisco M, Delgado-Lopez JM, Varoni EM et al. Cell Surface Receptor Targeted Biomimetic Apatite Nanocrystals for Cancer Therapy. Small. 2013;9:3834-3844 doi:10.1002/smll.201202843
4. Iafisco M, Varoni E, Di Foggia M et al. Conjugation of hydroxyapatite nanocrystals with human immunoglobulin G for nanomedical applications. Colloids and Surfaces B:Biointerfaces 2012;90;1-7
5. Sandhöfer B, Meckel M, Delgado-López JM et al. Synthesis and Preliminary in Vivo Evaluation of Well-Dispersed Biomimetic Nanocrystalline Apatites Labeled with Positron Emission Tomographic Imaging Agents. ACS Applied Materials and Interfaces 2015;7;10623–10633
6. Xie G, Sun J, Zhong G et al. Hydroxyapatite nanoparticles as a controlled-release carrier of BMP-2: absorption and release kinetics in vitro. J Mater Sci: Mater Med 2010;21;1875-1880
7. Ignjatović N, Djurić SV, Mitić Ž et al. Investigating an organ-targeting platform based on hydroxyapatite nanoparticles using a novel in situ method of radioactive 125Iodine labeling. Material Sciences and Engineering C 2014;43;439-446
8. Liu Y, Sun Y, Cao C et al. Long-term biodistribution in vivo and toxicity of radioactive/magnetic hydroxyapatite nanorods. Biomaterials 2014;35;3348-3355
9. Kozempel J, Vlk M, Málková E et. al. Prospective carriers of 223Ra for targeted alpha particle therapy. Journal of Radioanalytical and Nuclear Chemistry 2014;304;443-447
10. Kozempel J, Vlk M Nanoconstructs in Targeted Alpha-Therapy. Recent Patents on Nanomedicine 2014;4;71-76
11. Wang G, de Kruijff RM, Rol A et al. Retention studies of recoiling daughter nuclides of 225Ac in polymer vesicles. Applied Radiation and Isotopes 2014;85;45-53
12. European medicine agency: European Pharmacopoeia [online] 2014, [cit. 2015-06-25]. Dostupné na: http://www.ema.europa.eu
13. Guseva LI, Tikhomirova GS, Dogadkin NN An 227Ac-221Pb generator for test experiments of solution chemistry of element. Journal of Radioanalytical and Nuclear Chemistry 2004;260;167-172
14. Rehman I, Bonfield W Characterization of hydroxyapatite and carbonated apatite by photo acoustic FTIR spectroscopy. Journal of Materials Sciences: Materials in Medicine 1997;8;1-4
Labels
Nuclear medicine Radiodiagnostics RadiotherapyArticle was published in
Nuclear Medicine
![Issue 1](https://www.prolekare.cz/media/cache/resolve/journal_issue/media/image_pdf/3d25d783dafde0866ee861ce2b9a9698.jpeg)
2016 Issue 1
Most read in this issue
- Flare phenomenon in patient with breast cancer
- Scintigraphic detection of hemangioma – case report
- Reflection of introduction and application of PET/MR hybrid imaging systems in the Czech Republic
- Preparation of hydroxyapatites lebelled with 223Ra and 99mTc and their in vitro stabililty